If you could vote on Brexit now which option would you choose?

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.

NEJM.org - October 14, 2020

View the full story here: https://www.nejm.org/doi/full/10.1056/NEJMoa2027906